{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-006343","form_type":"8-K","ticker":"ASBP","cik":"0001847345","company_name":"Aspire Biopharma Holdings, Inc.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.520820+00:00","generated_at":"2026-05-16T03:06:15.694456+00:00","sec_items":["1.01","3.02","8.01","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aspire Biopharma raises up to $21M via convertible preferred stock; board adds Balatsos","bullets":["Initial closing of 13,750 Series A Convertible Preferred Shares for $11M gross proceeds; up to $21M total available.","Preferred shares convertible into common at 80% of lowest 5-day VWAP prior to conversion, subject to 4.99% ownership cap.","Company expects to regain Nasdaq stockholders' equity compliance (min $2.5M) after the offering.","Donald G. Fell resigned from board; Philip Balatsos appointed to fill vacancy.","RBW Capital Partners acted as placement agent; proceeds to support operations and reduce legacy debt."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-006343","json":"https://secwatch.observer/filing/0001493152-26-006343.json","markdown":"https://secwatch.observer/filing/0001493152-26-006343.md","text":"https://secwatch.observer/filing/0001493152-26-006343.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847345/000149315226006343/0001493152-26-006343-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847345/000149315226006343/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:06:15.694456+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a203fccaf33d38bcd0041c345488af52669bbab7","claim":"Aspire Biopharma Holdings, Inc. issued up to 25,000 shares of preferred stock to certain accredited investors for $11,000,000 aggregate gross proceeds.","evidence_excerpt":"Rule 5636(d) (“ Shareholder Approval ”). Pursuant to the Securities Purchase Agreement, the Company closed on an aggregate of 13,750 Shares resulting in gross proceeds of $11,000,000 including the conversion of $943,801 in existing debt into Shares on the same terms, before deducting fees to be paid to the placement agents and financial advisors of the Company","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315226006343/0001493152-26-006343-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"preferred stock"},{"label":"Shares","value":"up to 25,000 shares"},{"label":"Purchaser","value":"certain accredited investors"},{"label":"Consideration","value":"$11,000,000 aggregate gross proceeds"}],"fact_type":"equity_issuance"},{"claim_id":"aa83ecfcfd77bbf224d428309531db0db62c4972","claim":"Aspire Biopharma Holdings, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at $11,000,000 (effective 2026-02-06).","evidence_excerpt":"On February 6, 2026, Aspire Biopharma Holdings, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain accredited investors","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315226006343/0001493152-26-006343-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"$11,000,000"},{"label":"Effective","value":"2026-02-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}